CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Concord Biotech Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Concord Biotech Ltd
10th Floor
Nr. Prahladnagar Garden, 100ft Road
Phone: +91 7968138700p:+91 7968138700 AHMEDABAD, 380015  India Ticker: CONCORDBIOCONCORDBIO
Business Summary
Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic process and finished formulations. The Company’s offerings span both bio-pharmaceutical APIs and formulations across therapeutic areas like immunosuppressants oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in anti-bacterial, anti-fungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, Teicoplanin, Polymyxin B Sulfate, Fidaxomicin, Anidulafungin. Its API products under development include Daptomycin, Epirubicin, Idarubicin, and Pirarubicin.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Managing Director SudhirVaid 70 1/1/2015 5/10/2000
Chief Executive Officer, Joint Managing Director, Executive Director AnkurVaid 41 1/1/2018 12/4/2009
Chief Financial Officer LalitSethi 3/14/2022 3/14/2022
9 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1,377 (As of 3/31/2024)
Outstanding Shares: 104,616,204 (As of 9/30/2024)
Shareholders: 83,803
Stock Exchange: NSE
Fax Number: +91 2714222504


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024